13F Holdings
中文EN

ADAG Adagene Inc. Annual reports only

Pharmaceutical Preparations · Nasdaq · SEC CIK 1818838 · Fiscal year ends 12/31

Financial factors as of 2025-12-31 (FY2025), by fiscal year; growth vs the previous fiscal year

Growth

TTM revenue YoY7,332.8%
TTM net income YoY47.3%
TTM EPS YoY49.2%
Revenue 3-yr CAGR-6.2%
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin-279.5%
Net margin-229.6%
FCF margin-204.3%
EBITDA margin-273.8%

Returns

ROE-41.0%
ROA-21.0%
ROIC (approx.)—
Asset turnover0.09x

Leverage & solvency

Liabilities / assets33.7%
Debt / equity0.17x
Current ratio3.07x
Interest coverage-46.29x

Cash quality & payout

Operating cash flow / net income0.89x
Accruals ratio-2.3%
Payout ratio—
Capex / revenue0.2%

Factor history charts and full statement history on Pro 🔒

Financial statements

Annual Quarterly (none) Export CSV 🔒
Line item FY20252025-12-31FY20242024-12-31FY20232023-12-31FY20222022-12-31FY20212021-12-31
Income statement
Revenue$7.67M$103,204$18.11M$9.29M$10.18M
R&D expense$22.03M$28.78M$36.64M$81.34M$68.10M
SG&A expense$7.08M$7.27M$8.67M$11.87M$14.44M
Operating income-$21.44M-$35.95M-$23.72M-$83.92M-$72.36M
Interest expense$463,132$851,874$1.11M$693,323$363,762
Pretax income-$17.91M-$33.44M-$17.25M-$79.51M-$71.48M
Income tax-$297,860-$17,553$1.69M$459,055$1.70M
Net income-$17.61M-$33.42M-$18.95M-$79.97M-$73.18M
EBITDA-$21.00M-$35.23M-$22.74M-$82.77M-$71.24M
EPS (basic)-0.30-0.59-0.35-1.48-1.46
EPS (diluted)-0.30-0.59-0.35-1.48-1.46
Weighted avg. shares (diluted)59.01M56.29M54.74M54.14M50.03M
Balance sheet
Cash & equivalents$74.52M$85.19M$109.93M$143.76M$174.39M
Short-term investments$0$0$0——
Receivables————$3.00M
Current assets$77.38M$87.78M$113.44M$149.32M$185.95M
PP&E, net$717,374$1.13M$1.84M$2.78M$3.49M
Total assets$78.26M$89.27M$115.73M$152.40M$189.51M
Current liabilities$25.17M$38.18M$31.46M$55.08M$29.82M
Short-term debt$4.98M$17.79M$8.40M$13.62M$4.50M
Long-term debt$1.14M$417,339$13.54M$14.15M$2.99M
Total debt$6.12M$18.21M$21.94M$27.77M$7.49M
Total liabilities$26.36M$38.74M$45.17M$69.31M$32.95M
Shareholders' equity$35.35M$50.52M$70.56M$83.09M$156.56M
Net debt-$68.41M-$66.98M-$88.00M-$115.99M-$166.90M
Shares outstanding59.23M58.89M55.15M54.07M54.60M
Cash flow statement
Operating cash flow-$15.66M-$29.70M-$28.45M-$48.61M-$43.41M
Capital expenditure$17,053$33,580$85,012$690,938$2.51M
Free cash flow-$15.67M-$29.73M-$28.54M-$49.30M-$45.92M
Investing cash flow$476,803$1.11M-$77,356-$686,046-$2.51M
Financing cash flow$4.45M$3.77M-$5.37M$17.82M$145.36M
Depreciation & amortization$438,864$722,950$980,053$1.15M$1.13M
Stock-based compensation$3.74M$4.91M$7.27M$10.52M$18.68M
Share buybacks———$3.98M$2.36M

Free plan shows the latest 5 periods; Pro shows all 8 🔒

· This company files only annual reports with the SEC (20-F for foreign issuers), so there is no quarterly data; factors are by fiscal year and growth is vs the previous fiscal year.

· This company does not report gross profit in XBRL.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.